Skip to content

Clinical efficacy of radioactive iodine 125 particle implantation in the treatment of non-central pelvic recurrent cervical cancer after radiotherapy

Clinical efficacy of radioactive iodine 125 particle implantation in the treatment of non-central pelvic recurrent cervical cancer after radiotherapy

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071955
Enrollment
Unknown
Registered
2023-05-30
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

Sponsors

Hebei Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) The patient voluntarily participates in the study and signs an informed consent form; (2) Age 18-80 years old, PS score 0-2 points, expected survival of more than 3 months; (3) The primary tumor is pathologically confirmed to be malignant, all cases are confirmed by imaging or puncture biopsy, and there are no indications for re-surgery or refusal of surgical treatment; (4) CT, MRI or PET-CT shows relapsed or recurrent non-central cervical cancer after metastatic radiotherapy, with at least one measurable lesion; (5) Blood count: white blood cell count=3×109/L, neutrophil absolute value = 1.5×109/L, platelet count =75×1012/L, hemoglobin = 90g/L; There are no abnormalities in coagulation function

Exclusion criteria

Exclusion criteria: (1) Pregnant, lactating women or patients of childbearing age with family planning; (2) Serious organ dysfunction, such as severe heart, lung, liver and kidney insufficiency; (3) Severe coagulation dysfunction; (4) Persons with mental abnormalities or a history of mental illness (5) refuse to receive radiation therapy; (6) Researchers confirm that radiation therapy is not suitable. And it is < 3 months since the end of the last external radiation therapy.

Design outcomes

Primary

MeasureTime frame
Local control rate;

Secondary

MeasureTime frame
Objective and efficient;Pain relief rate;OS;quality of life;complication;Dosimetry;

Countries

China

Contacts

Public ContactDi xue min

Hebei Provincial People's Hospital

haitangbuyu@qq.com+86 187 3319 8812

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026